Delta Plus variant
- Scientists around the world and in India are concerned about ‘Delta plus’, an emerging form of the Delta variant of the novel coronavirus.
- This variant allows the virus to “escape” antibodies in recently approved treatment regimes.
WHAT IS DELTA PLUS VARIANT?
- Formally known as AY.1 or B.1.617.2.1, it’s a variant of Delta (B.1.617.2), which was first identified in India.
- It has an additional mutation called K417N, which has previously been identified in the Beta variant (first found in South Africa) and the Gamma variant (first detected in Brazil).
- The K417N, along with another mutation called K417T, is a mutation in the spike protein of the novel coronavirus.
- These variants are characterized as being highly infectious and may reduce the potency of vaccines.
WHY THE CONCERN?
- The Delta variant is now regarded as the most prevalent one in India, comprising nearly 31% of the 21,000 community samples processed until late May.
- This variant has significant differences compared to the strain that has been used by pharma companies to design vaccines,
- Tests are needed to check if the existing vaccines continue to be effective against the variants dominant now.
- Vaccines, while effective, appear to produce fewer antibodies when confronted with variants such as Delta.
- The concern is that because the Delta variant has a cavalcade of mutations that have allowed it to dominate in several countries, including India, another form may pose new challenges to the management of the pandemic in India.
Comments
Post a Comment